CRA was retained to develop a technology strategy to support improvements in drug discovery and development productivity. We profiled the company’s existing technology positions and assessed technology opportunities for its future. We created strategy options, supporting them with insights into technology and supplier evolution, and we considered how they could adopt new technology. Finally, CRA supported the key implementation decisions to divest existing technology, license/acquire new technology and monitor/experiment with emerging technology
From climate risk to resilience: what insurers must do next
In this article by Marakon’s Ofir Eyal, he discusses the crucial role insurers can take by financing and insuring green technologies and supporting the energy...